Bosutinib in the Management of Chronic Myelogenous Leukemia

Biologics: Targets and Therapy - New Zealand
doi 10.2147/btt.s30182
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Chronic Myelogenous Leukemia Molecular Signature

Oncogene
Cancer ResearchGeneticsMolecular Biology
2003English

Erythroid Variant of Chronic Myelogenous Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

The Role of Bosutinib in the Treatment of Chronic Myeloid Leukemia

Future Oncology
MedicineCancer ResearchOncology
2020English

Immunological Studies on Chronic Myelogenous Leukemia

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
1976English

Thrombotic Thrombocytopenic Purpura in Chronic Myelogenous Leukemia

Canadian Journal of Ophthalmology
MedicineOphthalmology
2020English

Evolution of Therapies for Chronic Myelogenous Leukemia

Cancer Journal
Cancer ResearchOncology
2011English

P53 in Chronic Myelogenous Leukemia in Acute Phase.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1991English

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing
Oncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy